This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Imbruvica
  • /
  • Combination of PCI-32765 With Obinutuzumab in Untr...
Clinical trial

Combination of PCI-32765 With Obinutuzumab in Untreated Follicular Lymphoma (Alternative)

Read time: 1 mins
Last updated:1st Feb 2016

Primary Objectives The primary objective of this study is to evaluate the efficacy of the chemotherapy-free combination of ibrutinib and obinutuzumab (GA 101) in patients with previously untreated follicular lymphoma (FL) and a high tumor burden. Primary endpoint to be observed for this is the rate of progression free survival one year after start of therapy.

Hypothesis The hypothesis of the study is that ibrutinib in combination with obinutuzumab will achieve response rates (CR and PR), rates of MRD negativity and PFS which are comparable to currently used standard rituximab-chemotherapy combinations such as R-CHOP or R-bendamustine in subjects with previously untreated FL and a high tumor burden.


Study Type: Interventional
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Chemotherapy-free Combination of the Bruton's Tyrosine Kinase Inhibitor, Ibrutinib in Combination With GA 101 in Patients With Previously Untreated Follicular Lymphoma and a High Tumor Burden
Estimated Enrollment: 98
Study Start Date: February 2016
Estimated Study Completion Date: July 2022
Estimated Primary Completion Date: June 2018 (Final data collection date for primary outcome measure)

Arms:
- Experimental:
Ibrutinib and GA 101

Category Value
Study start date 2016-02-01

View full details